Skip to main content
SpringerLink
Log in

Gastrointestinal Stromal Tumor of the Small Intestine: A Clinicopathologic Study of 70 Cases in the Postimatinib Era

  • Published:
World Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

The small intestine, after the stomach, is the second most common primary site for gastrointestinal stromal tumors (GISTs). This study aimed to identify clinicopathologic prognostic factors of tumor recurrence and survival and to analyze the influence of imatinib and sunitinib for small-intestine GISTs.

Methods

We reviewed the surgical experience of patients with small-intestine GISTs at National Taiwan University Hospital from January 1995 to March 2007. We analyzed the perioperative clinicopathologic data and treatment course.

Results

Seventy patients were included. The tumor was local in 43 patients, advanced in 21 patients, and 6 had metastasis. The median size of the tumor was 6.5 cm. Forty-four patients had a mitotic rate of less than 5/50 high-power field. The 1-year and 5-year disease-free survival rates were 85 and 66.7%, respectively, while the 1-year and 5-year overall survival rates were 98.5 and 86.6%, respectively. There were 19 patients with recurrent disease and 6 patients died of intestinal GISTs. The response rate of imatinib and sunitinib were 73.3 and 60%, respectively. According to multivariate analysis for disease recurrence, only invasion status, tumor size, and mitotic rate are significant (P = 0.007, 0.035, 0.007 respectively). They are also associated with poor survival (P ≤ 0.001, 0.006, 0.002, respectively).

Conclusions

The invasion status, size, and mitotic rate of tumor involve higher risk of recurrence and poor survival in small-intestine GISTs. The patients with recurrent small-intestine GISTs may have a lower mortality rate after using imatinib and sunitinib.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Mazur MT, Clark HB (1983) Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol 7:507–519

    Article  PubMed  CAS  Google Scholar 

  2. Kindblom LG, Remotti HE, Aldenborg F et al (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152:1259–1269

    PubMed  CAS  Google Scholar 

  3. Hirota S, Isozaki K, Moriyama Y et al (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279:577–580

    Article  PubMed  CAS  Google Scholar 

  4. DeMatteo RP, Lewis JJ, Leung D et al (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231:51–58

    Article  PubMed  CAS  Google Scholar 

  5. Miettinen M, Makhlouf HR, Sobin LH et al (2006) Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum: a clinicopathologic, immunohistochemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. Am J Surg Pathol 30:477–489

    Article  PubMed  Google Scholar 

  6. Fletcher CD, Berman JJ, Corless C et al (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33:459–465

    Article  PubMed  Google Scholar 

  7. Demetri GD, von Mehren M, Blanke CD et al (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347:472–480

    Article  PubMed  CAS  Google Scholar 

  8. Dagher R, Cohen M, Williams G et al (2002) Approval summary: imitanib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 8:3034–3038

    PubMed  CAS  Google Scholar 

  9. Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomized controlled trial. Lancet 368:1329–1338

    Article  PubMed  CAS  Google Scholar 

  10. U.S. Food and Drug Administration. FDA approves new treatment for gastrointestinal and kidney cancer, P06-11. Available at http://www.fda.gov/bbs/topics/news/2006/NEW01302.html. Accessed 26 Jan 2006

  11. Brainard JA, Goldblum JR (1997) Stromal tumors of the jejunum and ileum: a clinicopathologic study of 39 cases. Am J Surg Pathol 21:407–416

    Article  PubMed  CAS  Google Scholar 

  12. Ma CK, De Peralta MN, Amin MB et al (1997) Small intestinal stromal tumors: a clinicopathologic study of 20 cases with immunohistochemical assessment of cell differentiation and the prognostic role of proliferation antigens. Am J Clin Pathol 108:641–651

    PubMed  CAS  Google Scholar 

  13. Crosby JA, Catton CN, Davis A et al (2001) Malignant gastrointestinal stromal tumors of the small intestine: a review of 50 cases from a prospective database. Ann Surg Oncol 8:50–59

    Article  PubMed  CAS  Google Scholar 

  14. Winfield RD, Hochwald SN, Vogel SB et al (2006) Presentation and management of gastrointestinal stromal tumors of the duodenum. Am Surg 72:719–723

    PubMed  Google Scholar 

  15. Chiu YC, Lin JW, Changchien CS et al (2005) Clinicopathological characteristics and prognosis of patients with small intestinal stromal tumors. J Formosa Med Assoc 104:905–912

    Google Scholar 

  16. Tworek JA, Appelman HD, Singleton T et al (1997) Stromal tumors of the jejunum and ileum. Mod Pathol 10:200–209

    PubMed  CAS  Google Scholar 

  17. Wu TJ, Lee LY, Yeh CN et al (2006) Surgical treatment and prognostic analysis for gastrointestinal stromal tumors (GISTs) of the small intestine: before the era of imatinib mesylate. BMC Gastroenterol 6:29

    Article  PubMed  Google Scholar 

  18. Lai IR, Chen CN, Lin MT et al (2008) Surgical treatment of gastric gastrointestinal stromal tumors: analysis of 92 operated patients. Dig Surg 25:208–212

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei, Taiwan, Republic of China

    Chun-Chieh Huang, Ching-Yao Yang, I-Rue Lai, Chiung-Nien Chen, Po-Huang Lee & Ming-Tsan Lin

Authors
  1. Chun-Chieh Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ching-Yao Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I-Rue Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Chiung-Nien Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Po-Huang Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming-Tsan Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ming-Tsan Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Huang, CC., Yang, CY., Lai, IR. et al. Gastrointestinal Stromal Tumor of the Small Intestine: A Clinicopathologic Study of 70 Cases in the Postimatinib Era. World J Surg 33, 828–834 (2009). https://doi.org/10.1007/s00268-009-9918-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00268-009-9918-4

Keywords

Search

Navigation